SCHEMBL31728545

SCHEMBL31728545

Nc1ncnc2c(-c3cccc(Cl)c3Cl)c(F)ccc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DGAT1 O75907 2/20 0.39
▸ CYP2D6 P10635 1/20 0.38
▸ MAOA P21397 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ ADRA1A P35348 1/20 0.38
▸ SCN4A P35499 1/20 0.38
▸ BLM P54132 1/20 0.38
▸ PMP22 Q01453 1/20 0.38
▸ PDE3A Q14432 1/20 0.38
▸ SCN5A Q14524 1/20 0.38
▸ SCN9A Q15858 1/20 0.38
▸ SCN2A Q99250 1/20 0.38
▸ SCN3A Q9NY46 1/20 0.38
▸ SCN10A Q9Y5Y9 1/20 0.38
▸ MAP4K4 O95819 7/20 0.37
▸ NUDT1 P36639 1/20 0.36
▸ LIMK1 P53667 2/20 0.36
▸ BRAF P15056 1/20 0.36
▸ CLK1 P49759 2/20 0.35
▸ PTPN11 Q06124 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31729221 0.81 DGAT1 (0.41) DGAT1CYP2D6MAOAMAPK1ADRA1A
SCHEMBL31728633 0.76 MAP4K4 (0.41) DGAT1CYP2D6MAOAMAPK1ADRA1A
SCHEMBL30207675 0.75 PTPN11 (0.38) MAPK1NUDT1PTPN11
SCHEMBL31728253 0.74 PDE5A (0.42) MAP4K4LIMK1
SCHEMBL31727770 0.73 PTPN11 (0.39) DGAT1PTPN11
SCHEMBL31727897 0.71 LIMK1 (0.36) MAP4K4LIMK1
SCHEMBL31727873 0.70 SMN1; SMN2 (0.40) DGAT1CYP2D6MAOAMAPK1ADRA1A
SCHEMBL2499259 0.70 KMT2A (0.43) CYP2D6MAOAMAPK1ADRA1ASCN4A
SCHEMBL31728484 0.69 PDE5A (0.46) CYP2D6MAPK1MAP4K4LIMK1CLK1
SCHEMBL2775914 0.69 MAP4K4 (0.44) MAP4K4LIMK1CLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025235874-A1 HETEROCYCLICS AS EGFR INHIBITORS SCHRÖDINGER, INC. (US) 2025-11-13 — — WO disclosed
Send feedback